|Day's Range||58.76 - 59.12|
|52 Week Range||53.55 - 69.24|
|PE Ratio (TTM)||-4.93|
|Expense Ratio (net)||0.57%|
Combined sales for Januvia and Janumet were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16.
On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.
Gilead beat Zacks EPS estimates, but missed on revenue, in the first quarter of 2017.